Eculizumab cessation in atypical hemolytic uremic syndrome.

Mednet Member

Hematology · University of Minnestoa

My approach to eculizumab cessation in aHUS is to at least consider cessation in all patients not only given the high cost of the drug, but also given the risk of meningococcemia, which is incompletely protected against by vaccines.In treating aHUS, I initiate eculizumab (and preventive therapy for ...